PMCID: PMC3630641.
NHS funding criteria are narrower than the licensed indication, with specific BMI thresholds and time-limited use
Baseline A1c was 7.57% and the placebo-adjusted A1c reductions were 0.36% and 0.41% with sotagliflozin 200 and 400 mg, respectively, at 24 weeks and 0.25% and 0.31% at 52 weeks (all P 30 mL/min/1.73 m 2 but 10-fold increase in GLP-1, which can delay gastric emptying and increase satiety
manufacturer recommends against use) Women with a documented hypersensitivity reaction to semaglutide or tirzepatide excipients These restrictions appear directly in FDA-approved labeling and are not at the discretion of a telehealth clinician
Look for products with: Stated GHK-Cu concentration (not just contains copper peptides) Opaque or tinted packaging to protect from light Reasonable formulation that doesnt include strong acids in the same product Cool storage recommendations followed Documented stability or third-party testing where available Avoid products with: Vague active ingredient labels Clear bottles in bright store displays (probably degraded) Very low GHK-Cu concentrations buried in proprietary blends Prices that dont match concentration or brand quality Key Takeaway: Injectable GHK-Cu protocols typically use 1 to 5 mg subcutaneously several times per week, but published evidence for this route is limited Can I Combine GHK-Cu with Other Actives
Excess visceral fat (deep abdominal fat surrounding organs) is associated with increased cardiovascular risk, insulin resistance, and metabolic syndrome